Point72 Asset Management
UTHR icon

Point72 Asset Management’s United Therapeutics UTHR Stock Holding History

Point72 Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.29M Buy
+10,600
New +$5.28M 0.01% 1545

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Point72 Asset Management's UTHR Position: Q1 2026 in Review

Point72 Asset Management reduced its United Therapeutics (UTHR) stake by 20% in Q1 2026, selling an estimated $18.4M and leaving 149,303 shares worth $88.5M. The position accounts for 0.11% of the portfolio, ranked #195.

Point72 Asset Management first reported a position in UTHR in Q3 2014 and has held it in 22 quarters since. The position peaked at $99.1M in Q2 2021. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Point72 Asset Management held 149,303 shares of United Therapeutics worth $88.5M as of Q1 2026.
  • Point72 Asset Management sold 36,861 United Therapeutics shares in Q1 2026, an estimated $18.4M.
  • United Therapeutics made up 0.11% of Point72 Asset Management's portfolio in Q1 2026, its #195 holding.
  • Point72 Asset Management first reported a position in United Therapeutics in Q3 2014 and has held it in 22 quarters since.
  • Point72 Asset Management's United Therapeutics position peaked at $99.1M in Q2 2021.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.